Objective: SGLT2 inhibitor (SGLT2i) should be considered for people with CKD with type 2 diabetes (T2D) . Since eGFR declining speed and responsiveness to SGLT2i are different in each person, we assessed renal protective effects by individual eGFR slope analysis.

Methods: A total of 75 patients with T2D with advanced CKD stage 3-4, treated by SGLT2i (empagliflozin 65% and others) were analyzed. The duration of diabetes at the time of recruitment were as follows: stage 3a (n=29) ; 11.9±5.4, stage 3b (n=28) ; 19.9±12.1, and stage 4 (n=18) ; 13.8±8.5 years. The mean of age was 70.3±12.2 year-old. GLP-1RAs was used in 41%, 64% and 44% respectively. Most rapid baseline eGFR slopes were calculated from 45.7±19.9 months before using SGLT2i, and slopes after adding SGLT2i were calculated from 39.2±11.4 months.

Results: 1) In total, the initiation of SGLT2i decreased eGFR from 46.1±14.1 to 43.6±13.5ml/min/1.73m2 (P<0.001) on the first month. 2) In total, averaged individualized eGFR slopes were improved from -6.4±9.1 to -1.5±3.2ml/min/1.73m2/year (P<0.001) . The rate of responders (responder: defined as slope are attenuated vs. baseline) in each stage were as follows: stage 3a; (22/29) , stage 3b; (22/28) , stage 4; (16/18) . Slopes in responders (60/75) were improved as follows, -7.5±9.8 to -0.8±3.0 ml/min/1.73m2/year (P<0.001) . Slopes in non-responders (15/75) were worsened as follows, -2.0±2.0 to -4.0±3.2ml/min/1.73m2/year (P<0.001) . Although no clear background differences could be found, responders were more rapid eGFR decliners and highly had macro-albuminuria (53% vs. 33%) . 3) Slopes were improved in all stages, stage 3a: -4.1±3.7 to -1.2±3.2 (P<0.001) and stage 3b; -4.9±3.7 to -1.3±3.1 (P<0.001) , and stage 4; -12.4±16.3 to -2.0±3.6ml/min/1.73m2/year (P<0.01) . In stage 4, nephrosis highly existed in 28% at the baseline.

Conclusion: To pursuit the renal benefits safely, especially starting SGLT2i in lower eGFR level in people with advanced CKD stages, individualized slope analysis is needed.


K.Kashima: None. H.Shimizu: None. M.Yamada: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.